IMUGENE LIMITED — Board/Management Information 2021

Nov 21, 2021

==> picture [116 x 42] intentionally omitted <==

ASX Announcement

Ceasing to be a Director

---

Sydney, Australia, November 22, 2021

Further to the announcement of the results of the 2021 Annual General Meeting on Friday 19 November, Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company, advises that pursuant to Resolution 2 Dr Axel Hoos has not been re-elected as a non-executive director of the Company. Dr Hoos was appointed in December 2013.

Imugene Chairman Mr Paul Hopper on behalf of the Board thanks Dr Hoos for his contribution to

Imugene’s growth and development and wish him well for his future activities.

For more information please contact:

Leslie Chong Managing Director and Chief Executive Officer info@imugene.com Investor Enquiries investor@imugene.com

Media Enquiries

Matt Wright matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene Like us on Facebook @Imugene Connect with us on LinkedIn @Imugene Limited

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

About Imugene (ASX: IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immunooncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia

2 551

IMUGENE LIMITED

ACN 009 179